U3 Pharma AG

German start-up U3 Pharma AG is hoping that its focus on, and understanding of, full biological systems rather than simply on chemistry will give it a chance to win the race to find new cancer drugs.

The illusion that the uncovering of the genome and automated, high-throughput discovery technologies would generate a plethora of new, validated drug leads has long been shattered. Drug discovery companies have had to get cleverer than that. Many focus on well-known target classes, such as G-protein coupled receptors (GPCRs), protein kinases, or the gene families associated with these. Others have tried to carve a niche by going for targets that have for one reason or another proven intractable. (See "Accelerating Small Molecule Drug Discovery," START UP, September 2000 Also see "Accelerating Small Molecule Drug Discovery" - Scrip, 1 September, 2000..)

All are going for speed, though. German start-up U3 Pharma AG is no exception: its goal is to get...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

More from In Vivo